by MM360 Staff | Jun 3, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | Jun 3, 2025 | Uncategorized
Source: CureToday articles Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC. Read More
by MM360 Staff | Jun 3, 2025 | Uncategorized
Source: CureToday articles Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer. Read More
by MM360 Staff | Jun 3, 2025 | Myeloma News
Source: Pharmacy Times articles The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases. Read More
by MM360 Staff | Jun 3, 2025 | Myeloma News
Source: Pharmacy Times articles The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial. Read More